VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Vericel Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$40.37+0.24 (+0.60%)

Close on Oct 19, 2026

Market cap: $2.11B
P/E (TTM): 96.1
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$276.26MFY2025, +77.6% a year since FY2010

Where these numbers come from

Parsed from the XBRL in Vericel's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Oct 16, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VCEL.

Revenue growth23.0% · median 16.5%

Gross margin74.6% · median 53.8%

Operating margin6.0% · median 8.2%

Net margin7.9% · median 5.3%

Company	Revenue	Growth
RGEN	$785.10M	+16.5%
ADMA	$512.28M	+8.0%
ORGO	$457.45M	+6.5%
KRYS	$440.48M	+22.6%
IOVA	$324.97M	+34.5%
VCEL	$306.30M	+23.0%

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 398
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 887359

Advertisement
300 × 250